|
|
 |
|
Viewing report
|
|
|
|
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
TriMark Publications, April 2008, Pages: 355
Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful.
The purpose of this report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. This study particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor’s offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer.
The main objectives of this analysis are:
- Identifying viable technology drivers for cancer biomarkers and related companion diagnostics through a comprehensive look at platform technologies including, probe-based nucleic acid assays, microarrays and sequencing, and mass spectroscopy.
- Obtaining a complete understanding of the new cancer biomarker diagnostic tests-i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic-from their basic principles to their applications.
- Discovering growing market opportunities by identifying high-growth applications in different cancer diagnostic areas, focusing on the biggest and expanding markets in oncology (e.g., biomarkers for breast cancer and predictive biomarkers).
- Focusing on global industry development through an in-depth analysis of the major world markets for cancer diagnostics, including growth forecasts.
This analysis emphasizes companies that are actively developing and marketing new reagents and supplies for performing cancer biomarker diagnostics tests. It discusses the various market trends and opportunities using new biomarkers, while providing an in-depth analysis of market share, revenue forecasts, and market drivers and restraints. The comprehensive focus of the study, backed by strategic recommendations, enables companies to position their growth strategies to benefit from the changing market conditions and obtain maximum return on investment.
This study surveys biotech companies known for marketing, manufacturing or developing instruments and reagents for the clinical cancer diagnostics market, both in the U.S. and the world. Leading companies are discussed in-depth, with sections on the companies' histories, product lines, business and marketing analyses, and subjective commentary on the companies' market positions.
This report answers the questions:
- Which companies are utilizing cutting-edge technologies to develop, validate, and implement cancer biomarkers for clinical use?
- What impediments still exist to incorporating promising research into clinical practice?
- Which cancer biomarkers show the most promise for approval?
- What are the economic challenges to approval?
- How can regulatory oversight drive approval and adoption of new technologies?
- Which alliances show the greatest synergy in bringing valid biomarkers to market?
- Which shared technologies are driving the most encouraging development?
Product samples
Samples for this product is available. Please Login/Register to download these samples.
Also available
Cancer Diagnostic Testing World Markets
Cancer Cell Therapy Markets
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Cancer Therapeutics Markets
Cytology and HPV Testing World Markets
Cancer Bundle
Customers who bought this item also bought
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Cancer Personalized Medicine 2008
Cancer Biomarkers: Players, Products and Prospects (Volume I)
MicroRNA Diagnostics, Therapeutics, and Cancer Personalized Medicine 2009 Market Report
Companion Biomarkers in Drug Development
The German Cancer Diagnostics Market
The US Cancer Diagnostics Market
The Spanish Cancer Diagnostics Market
The French Cancer Diagnostics Market
The UK Cancer Diagnostics Market
The Japanese Cancer Diagnostics Market
Cancer Diagnostic Testing World Markets
|
|
|
|
